45 results about "IRAK4" patented technology

Compounds of the formula I or II:wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b] pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Compounds within the scope of the present invention have a Formula 1or a salt or prodrug thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and heteroaryl; and R2 and R3 are independently selected from hydrogen and (C1-C6)alkyl. Disclosed compounds may have an IRAK4 IC50 of from 0.003 μM to 3.7 μM; a TAK1 IC50 of from 0.008 μM to 132 μM; and / or an IRAK4 / TAK1 selectivity of from 1 to 450. Particular compounds may have an IRAK4 / TAK1 selectivity of from 100 to 500. Disclosed compositions may be formulated as pharmaceutical compositions. A method for using the compounds and / or compositions also are disclosed. The method may comprise administering to a subject an effective amount of a compound within the scope of the present invention, particularly to selectively inhibit IRAK 1 and / or IRAK4 over TAK1.

Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

The present application relates to a novel combination product of at least two components (component A and component B) for the treatment and / or prevention of diseases: component A is an IRAK4 inhibitory compound of formula (I) as defined herein, or a diastereomer, enantiomer, metabolite, salt, solvate or solvate of a salt thereof; component B is a BTK inhibitory compound, or a pharmaceutically acceptable salt thereof; and, optionally One or more components C which are pharmaceutical products; wherein one or both of compounds A and B as defined above are optionally present in a pharmaceutical preparation intended for simultaneous, separate or sequential administration, And to its use for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and / or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.

Described herein are compounds of formula (0), formula (I) and formula (II) and methods of use as interleukin-1 receptor-associated kinase (IRAK4) inhibitors.